S-1: Applied DNA Sciences Seeks to Raise Capital Through Common Stock and Warrant Offering

Applied DNA Sciences is offering shares of common stock and warrants to fund the development of its Therapeutic DNA Production and MDx Testing Services.

Summary

• Applied DNA Sciences, Inc., a biotechnology company, has filed a Form S-1 registration statement for a proposed offering of its securities.
• The offering includes shares of common stock, Series A and Series B warrants to purchase common stock, and pre-funded warrants to purchase common stock, as well as placement agent warrants.
• The company intends to use the net proceeds from the sale of the securities for the further development of its Therapeutic DNA Production and MDx Testing Services, as well as for general corporate purposes.
• The company's common stock is listed on The Nasdaq Capital Market under the symbol APDN.
• The company is developing and commercializing technologies to produce and detect DNA and RNA, operating in three primary business markets: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services.
• The company plans to offer several quality grades of Linea DNA, each of which will have different permitted uses.
• The company plans to offer Linea DNA materials manufactured under GMP suitable for use as, or incorporation into, a biologic, drug substance and/or drug product, with availability expected during the second half of calendar year 2025, dependent upon the availability of future funding.
• The company's pharmacogenomics testing services (the PGx Testing Services) will utilize a 120-target PGx panel test to evaluate the unique genotype of a specific patient to help guide the patients healthcare provider in making individual drug therapy decisions.
• The company's PGx Testing Services cannot commence until it receives approval from the NYSDOH.
• The company's Board of Directors believes that the reverse stock split is the best option available to increase the company's stock price as required for continued listing on Nasdaq and determined on April 21, 2024 that the split ratio should be one-for-twenty shares.
• The reverse stock split is expected to be effected as of 12:01 a.m. Eastern Time on Thursday, April 25, 2024 and will combine each twenty shares of the company's outstanding common stock into one share of common stock, without any change in the par value per share.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is pursuing growth opportunities and has innovative technologies, there are significant financial risks and uncertainties, including recurring losses, going concern doubts, and Nasdaq compliance issues. The capital raise itself is a necessity, not a sign of strength.

Positives

• The company's Linea DNA platform offers advantages over existing cell-based plasmid DNA manufacturing platforms, including speed, scalability, purity, simplicity, and flexibility.
• The company's Linea IVT platform enables customers to make better mRNA, faster, potentially increasing the company's mRNA-related total addressable market (TAM) by approximately 3x.
• The company's PGx Testing Services have the potential to significantly reduce overall population healthcare costs, reduce adverse drug events, and increase overall population wellbeing.
• The company's Board of Directors approved a one-for-twenty reverse stock split, expected to be effected on April 25, 2024.

Negatives

• The company has recurring net losses and an accumulated deficit of $303,630,004 as of December 31, 2023.
• There is substantial doubt relating to the company's ability to continue as a going concern.
• The company's PGx Testing Services cannot commence until it receives approval from the NYSDOH, and the timing of any approval is unclear.
• The company has received written notice from Nasdaq that it is not in compliance with Nasdaqs minimum bid requirements and if it is unable to regain compliance with Nasdaq continued listing standards it could be delisted from Nasdaq, which would negatively impact the company's business, the company's ability to raise capital, and the market price and liquidity of the company's common stock.
• The reverse stock split may adversely impact the market price of the company's common stock.

Risks

• The company may require additional financing which may in turn require the issuance of additional shares of common stock, preferred stock or other debt or equity securities (including convertible securities) and which would dilute the ownership held by or stockholders.
• The company's operating results have been and could be adversely affected by a reduction in business with the company's significant customers.
• The company's current emphasis on Therapeutic DNA Production Services may reduce the company's ability to maintain and expand the company's existing MDX Testing Services and DNA Tagging and Security Products and Services businesses.
• If the company is unable to expand the company's DNA manufacturing capacity, the company could lose revenue and the company's business could suffer.
• Rapidly changing technology and extensive competition in synthetic biology could make the services or products the company is developing obsolete or non-competitive unless the company continues to develop new and improved services or products and pursue new market opportunities.
• The company may be unable to consistently manufacture or source the company's products to the necessary specifications or in quantities necessary to meet demand on a timely basis and at acceptable performance and cost levels.
• The markets for drug and biologic candidates and synthetic DNA are very competitive, and the company may be unable to continue to compete effectively in these industries in the future.
• The company competes with life science, pharmaceutical and biotechnology companies, some of whom are the company's customers, who are substantially larger than the company is and potentially capable of developing new approaches that could make the company's products and technology obsolete or develop their own internal capabilities that compete with the company's products.
• The company's intellectual property rights are valuable, and any inability to protect them could reduce the value of the company's products, services and brand.
• Pharmaceutical and biologic-related revenue is generally dependent on regulatory approval, oversight and compliance.
• If the FDA were to begin to enforce regulation of laboratory-developed tests, the company could incur substantial costs and delays associated with trying to obtain pre-market clearance or approval and costs associated with complying with post-market requirements in respect of MDx Testing Services.
• If the company fails to comply with laboratory licensing requirements, the company could lose the ability to offer the company's MDx Testing Services or experience disruptions to the company's business.
• If the company fails to comply with healthcare laws, the company could face substantial penalties and the company's business, operations and financial conditions could be adversely affected.
• If the company is unable to continue to retain the services of Dr. Hayward, the company may not be able to continue the company's operations.
• There are a large number of shares of common stock underlying the company's outstanding options and warrants and the sale of these shares may depress the market price of the company's common stock and cause immediate and substantial dilution to the company's existing stockholders.
• The reverse stock split may decrease the liquidity of the shares of the company's common stock and the resulting market price of the company's common stock may not attract or satisfy the investing requirements of new investors, including institutional investors.
• The effective increase in the number of shares of the company's common stock available for issuance as a result of the company's reverse stock split could result in further dilution to the company's existing stockholders and have anti-takeover implications.

Future Outlook

The company intends to use the net proceeds from this offering for the further development of its Therapeutic DNA Production Services and MDx Testing Services, as well as general corporate purposes, which may include research and development expenses, capital expenditures, working capital and general and administrative expenses, and potential acquisitions of or investments in businesses, products and technologies that complement the company's business.

Industry Context

The company operates in the biotechnology industry, focusing on the development and commercialization of technologies to produce and detect DNA and RNA. The company's Therapeutic DNA Production Services target the rapidly growing market for nucleic acid-based therapeutics, including gene, cell, and RNA therapies. The company's MDx Testing Services provide clinical molecular diagnostics and genetic testing services. The company's DNA Tagging and Security Products and Services offer supply chain security solutions.

Comparison to Industry Standards

• The document does not contain enough information to make a detailed comparison to industry standards.
• To perform a detailed comparison, specific financial metrics (e.g., revenue growth, R&D spending, gross margins) would need to be compared against those of comparable companies in the biotechnology, synthetic biology, and molecular diagnostics industries.
• Comparable companies might include firms focused on DNA manufacturing (e.g., Twist Bioscience), mRNA therapeutics (e.g., Moderna, BioNTech), or supply chain security solutions (e.g., SICPA).

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• Shareholders face the risk of further stock price decline if the company fails to regain compliance with Nasdaq listing requirements.
• Employees may be affected by the company's financial performance and ability to execute its business strategy.
• Customers of the company's Therapeutic DNA Production and MDx Testing Services may benefit from the company's continued development and expansion of these services.

Next Steps

• The company plans to complete the offering of its securities.
• The company plans to further develop its Therapeutic DNA Production and MDx Testing Services.
• The company plans to create a fit for purpose manufacturing facility within its current Stony Brook, NY laboratory space capable of producing Linea DNA IVT templates under Good Manufacturing Practices (GMP) suitable for use as a critical starting material for clinical and commercial mRNA therapeutics, with a planned completion date in the third quarter of calendar year 2024.
• The company plans to offer Linea DNA materials manufactured under GMP suitable for use as, or incorporation into, a biologic, drug substance and/or drug product, with availability expected during the second half of calendar year 2025, dependent upon the availability of future funding.
• The company must file a response to the third set of comments received from NYSDOH regarding its PGx Testing Services by May 28, 2024.
• The company intends for the Reverse Stock Split to enable it to regain compliance with the Minimum Bid Price Requirement.

Key Dates

Keywords

Therapeutic DNA Production Services, MDx Testing Services, DNA Tagging, Linea DNA, Warrants, Common Stock, RNA, DNA, APDN